WO2012085935A3 - Diamide piperidine compounds as inhibitors of renin - Google Patents

Diamide piperidine compounds as inhibitors of renin Download PDF

Info

Publication number
WO2012085935A3
WO2012085935A3 PCT/IN2011/000870 IN2011000870W WO2012085935A3 WO 2012085935 A3 WO2012085935 A3 WO 2012085935A3 IN 2011000870 W IN2011000870 W IN 2011000870W WO 2012085935 A3 WO2012085935 A3 WO 2012085935A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
diamide
renin
piperidine compounds
synthesis
Prior art date
Application number
PCT/IN2011/000870
Other languages
French (fr)
Other versions
WO2012085935A2 (en
Inventor
Jigar Desai
Pravin Thombare
Mukul R. Jain
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2012085935A2 publication Critical patent/WO2012085935A2/en
Publication of WO2012085935A3 publication Critical patent/WO2012085935A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
PCT/IN2011/000870 2010-12-22 2011-12-19 Compounds as inhibitors of renin WO2012085935A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3487/MUM/2010 2010-12-22
IN3487MU2010 2010-12-22

Publications (2)

Publication Number Publication Date
WO2012085935A2 WO2012085935A2 (en) 2012-06-28
WO2012085935A3 true WO2012085935A3 (en) 2013-09-26

Family

ID=46314551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000870 WO2012085935A2 (en) 2010-12-22 2011-12-19 Compounds as inhibitors of renin

Country Status (2)

Country Link
AR (1) AR084546A1 (en)
WO (1) WO2012085935A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058387A1 (en) * 2006-11-17 2008-05-22 Merck Frosst Canada Ltd. Renin inhibitors
WO2008141462A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
WO2010122580A2 (en) * 2009-04-24 2010-10-28 Cadila Healthcare Limited Novel compounds as inhibitors of renin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058387A1 (en) * 2006-11-17 2008-05-22 Merck Frosst Canada Ltd. Renin inhibitors
WO2008141462A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
WO2010122580A2 (en) * 2009-04-24 2010-10-28 Cadila Healthcare Limited Novel compounds as inhibitors of renin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREENE, T.W.; WUTS, P.G.M.: "Protective Groups in organic synthesis - 3rd Edition", part N-Benzylamine (R2N-Bn) 1999, JOHN WILEY AND SONS, ISBN: 0-471-16019-9, pages: 579 - 580, XP002699619 *
GREENE, T.W.; WUTS, P.G.M.: "Protective groups in organic synthesis - 3rd Edition", part t-Butyl (BOC) Carbamate 1999, JOHN WILEY AND SONS, ISBN: 0-471-16019-9, pages: 518 - 522, XP002698650 *

Also Published As

Publication number Publication date
WO2012085935A2 (en) 2012-06-28
AR084546A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
WO2010105179A3 (en) Inhibitors of beta-secretase
MX342212B (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
MY165087A (en) Neprilysin inhibitors
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
MX347841B (en) Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorph of these derivatives.
MY170935A (en) Neprilysin inhibitors
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
MX354476B (en) Neprilysin inhibitors.
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX2013005833A (en) Novel fused pyridine compounds as casein kinase inhibitors.
JO3577B1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
MX2011007978A (en) Novel method for the synthesis of ivabradine and the pharmaceutically acceptable acid addition salts thereof.
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2010003213A (en) Novel method for the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
MX2010009876A (en) New process for the preparation of cyclohexanecarboxylic acid derivatives via the corresponding cyclohexanecarboxamide derivative.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2008059513A3 (en) Compounds suitable as modulators of hdl
MX2010003184A (en) Novel method for the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
WO2010122580A3 (en) Piperidine derivatives as inhibitors of renin
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
MX2010006218A (en) Organic compounds.
WO2012085935A3 (en) Diamide piperidine compounds as inhibitors of renin
WO2009053999A3 (en) Sulfoximine derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11851443

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11851443

Country of ref document: EP

Kind code of ref document: A2